The term castration-resistant prostate cancer (CRPC) encompasses a wide variety of patients with different prognoses.
The combination of docetaxel and prednisone is considered as the standard first-line chemotherapy. For years, patients progressing on docetaxel have been managed with second- and third-line hormone therapies, re-treatment with docetaxel, or combined mitoxantrone and prednisone. Recently published results of four studies using different drugs: cabazitaxel (CBZ), abiraterone (AA), enzalutamide (ENZ), and radium 223, showed an increased survival in such patients. In this article, authors make some considerations about criteria guiding the choice of a second-line chemotherapy after docetaxel in patients with metastatic CRPC, and propose an algorithm based on scientific evidence and consensus for rational use of cabazitaxel in this scenario.
Written by:
Gallardo E, Arranz JA, Maroto JP, León LA, Bellmunt J. Are you the author?
Department of Oncology, Parc Taulí Sabadell Hospital Universitari, Sabadell, Barcelona, Spain.
Reference: Crit Rev Oncol Hematol. 2013 Jul 15. pii: S1040-8428(13)00128-5.
doi: 10.1016/j.critrevonc.2013.06.008
PubMed Abstract
PMID: 23867574
UroToday.com Prostate Cancer Section
